South Korea-based International Vaccine Institute (IVI) has sigend a Memorandum of Understanding (MoU) with Nankai University, Tianjin, China for Designation and Operation of IVI Nankai Joint Vaccine Centre. This is the first Joint Research Institution that the International Vaccine Institute (IVI) establishes in China.

Moreover, the two parties will proactively connect with “Belt and Road” countries and low- and middle-income countries in terms of scientific research achievement transformation, technology transfer, and training of professionals.

The two parties wish to jointly establish a leading, exemplary, and innovative cooperation model, and contribute to strengthening the global public health security agenda and building a community of common health for humankind.

Nankai University has strong research strength and advantages in the field of public health and biomedicine and hopes to actively promote bilateral cooperation with IVI to carry out innovative vaccine research and development and provide international public goods. 

The cooperation between Nankai University and IVI has a good prospect and is of great practical significance. On one hand, it will be beneficial to the development of China’s vaccine industry and have a positive impact on relevant industries and economic development in Tianjin and even the whole country. On the other hand, combined with China’s actual production capacity, it will help alleviate the shortage of medical products in developing countries and promote the development of global public health.